by Sarah Woolnough, CEO of Asthma UK and the British Lung Foundation
News
NICE backs Lilly’s Taltz for axial spondyloarthritis
Drug has been cleared for use in patients whose condition is not controlled well enough with conventional therapy
CureVac’s COVID-19 vaccine misses the mark in late-stage study
Company attributed 47% vaccine efficacy to ‘unprecedented’ amount of circulating variants
Researchers develop COVID-19 antibody test to detect new variants
New antibody tests can detect if an individual has been exposed to COVID-19 variants, including Alpha and Delta variants
Lilly plans head-to-head migraine study comparing Emgality with Nurtec ODT
The primary endpoint of the study is a 50% reduction in monthly migraine headache days
Study demonstrates safety and efficacy of co-administering COVID-19 and flu vaccines
Study co-administered Novavax’s COVID-19 vaccine alongside Seqirus’ flu vaccines
Exscientia expands translational capabilities with Allcyte acquisition
Allcyte specialises in artificial intelligence (AI) based precision medicine
Biogen’s inherited eye disease gene therapy misses the mark in late-stage trial
Gene therapy was being evaluated for the treatment of the rare eye disease choroideremia
Imbruvica/Venclyxto tops Gazyva plus chemo in first-line CLL/SLL
Imbruvica treatment regimen demonstrated superior progression-free survival compared to Gazyva combo
AZ, Pfizer/BioNTech vaccines ‘highly effective’ against Delta variant
New real world data from PHE shows vaccines can protect against hospitalisation caused by variant
Novavax’s COVID-19 vaccine shows 90% efficacy in Phase III
Jab was also found to be 100% effective at preventing moderate to severe COVID-19
Opdivo plus Yervoy scores NICE backing for certain bowel cancer patients
Immunotherapy combo approved for the treatment of advanced bowel cancer patients with rare MSI-H/dMMR mutations
Vertex, CRISPR Therapeutics’ blood disorder gene therapy shows more promise
CTX001 is being evaluated as a one-time treatment for transfusion dependent beta thalassemia and sickle cell disease
NICE to reassess Kyowa Kirin’s Poteligeo
An appeal lodged by the company and various charities has been upheld by an independent appeal panel
UK to donate 100 million surplus COVID-19 vaccine doses
Gov’t will donate five million of the surplus doses by the end of September
